Clinical Trial

Vasodilator and Exercise Study for DMD (VASO-REx)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-03-01; most recent amendment 2026-05-12.
Status change: Not Yet Recruiting → Recruiting 2024-06-21
Trial Details
NCT Number NCT06290713
Lead Sponsor University of Florida
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions Duchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy, Muscular Dystrophy in Children, Vasodilation, Exercise, DMD
Enrollment 50 participants
Start Date 2024-06-05
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-15